Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Risedronic Acid"" wg kryterium: Temat


Tytuł :
Skeletal and mineral metabolic effects of risedronate in a rat model of high-turnover renal osteodystrophy.
Autorzy :
Ishida H; Department of Transplant Surgery, Tokai University School of Medicine, Isehara, Japan.
Komaba H; Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimo-Kasuya, Isehara, 259-1193, Japan. .; Interactive Translational Research Center for Kidney Diseases, Tokai University School of Medicine, Isehara, Japan. .; The Institute of Medical Sciences, Tokai University, Isehara, Japan. .
Hamano N; Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimo-Kasuya, Isehara, 259-1193, Japan.
Yamato H; Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimo-Kasuya, Isehara, 259-1193, Japan.
Sawada K; Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimo-Kasuya, Isehara, 259-1193, Japan.
Wada T; Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimo-Kasuya, Isehara, 259-1193, Japan.
Nakamura M; Department of Transplant Surgery, Tokai University School of Medicine, Isehara, Japan.
Fukagawa M; Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimo-Kasuya, Isehara, 259-1193, Japan.
Pokaż więcej
Źródło :
Journal of bone and mineral metabolism [J Bone Miner Metab] 2020 Jul; Vol. 38 (4), pp. 501-510. Date of Electronic Publication: 2020 Mar 05.
Typ publikacji :
Journal Article
MeSH Terms :
Bone Remodeling*/drug effects
Bone and Bones/*pathology
Chronic Kidney Disease-Mineral and Bone Disorder/*drug therapy
Chronic Kidney Disease-Mineral and Bone Disorder/*physiopathology
Minerals/*metabolism
Risedronic Acid/*therapeutic use
Animals ; Biomechanical Phenomena ; Blood Urea Nitrogen ; Bone and Bones/drug effects ; Bone and Bones/physiopathology ; Calcium/blood ; Chronic Kidney Disease-Mineral and Bone Disorder/blood ; Creatinine/blood ; Disease Models, Animal ; Gene Expression Regulation/drug effects ; Humans ; Male ; Nephrectomy ; Peptide Fragments/blood ; Phosphorus/blood ; Procollagen/blood ; Rats, Sprague-Dawley ; Risedronic Acid/pharmacology
Czasopismo naukowe
Tytuł :
Effects of teriparatide compared with risedronate in the treatment of osteoporosis: A meta-analysis of randomized controlled trials.
Autorzy :
Yang C; Department of spine osteopathic surgery, the first affiliated hospital of Guangxi medical University.; Trauma centers.
Le G; Department of arthropathy, the fourth affiliated hospital of Guangxi medical University.; Department of arthropathy, Guangxi liuzhou workers hospital.
Lu C; Department of spinal joint osteopathology.
Wei R; Department of orthopedic trauma, People's hospital of Hechi, Guangxi province, China.
Lan W; Department of orthopedic trauma, People's hospital of Hechi, Guangxi province, China.
Tang J; Trauma centers.
Zhan X; Department of spine osteopathic surgery, the first affiliated hospital of Guangxi medical University.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Feb; Vol. 99 (7), pp. e19042.
Typ publikacji :
Comparative Study; Journal Article; Meta-Analysis
MeSH Terms :
Osteoporosis/*drug therapy
Risedronic Acid/*therapeutic use
Teriparatide/*therapeutic use
Bone Density/drug effects ; Female ; Humans ; Randomized Controlled Trials as Topic ; Risedronic Acid/adverse effects ; Risedronic Acid/pharmacology ; Teriparatide/adverse effects ; Teriparatide/pharmacology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Phase II/III, randomized, double-blind, parallel-group study of monthly delayed-release versus daily immediate-release risedronate tablets in Japanese patients with involutional osteoporosis.
Autorzy :
Soen S; Department of Orthopedic Surgery and Rheumatology, Kindai University Nara Hospital, 1248-1 Otodacho, Ikoma, Nara, 630-0293, Japan. .
Kishimoto H; Department of Orthopedic Surgery, Nojima Hospital, Tottori, Japan.
Hagino H; School of Health Science and Rehabilitation Division, Tottori University, Yonago, Tottori, Japan.
Sone T; Department of Nuclear Medicine, Kawasaki Medical School, Kurashiki, Okayama, Japan.
Ohishi H; EA Pharma Co., Ltd., Chuo-ku, Tokyo, Japan.
Fujimoto T; Takeda Pharmaceutical Company Ltd., Chuo-ku, Osaka, Japan.
Sasaki E; Takeda Pharmaceutical Company Ltd., Chuo-ku, Osaka, Japan.
Tanaka S; Orthopedic Surgery, Sensory and Motor System Medicine, Surgical Sciences, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Sugimoto T; Internal Medicine 1, Shimane University, Faculty of Medicine, Izumo, Shimane, Japan.
Pokaż więcej
Źródło :
Journal of bone and mineral metabolism [J Bone Miner Metab] 2020 Jan; Vol. 38 (1), pp. 86-98. Date of Electronic Publication: 2019 Aug 16.
Typ publikacji :
Clinical Trial, Phase II; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Asian Continental Ancestry Group*
Osteoporosis/*drug therapy
Risedronic Acid/*therapeutic use
Aged ; Biomarkers/metabolism ; Bone Density/drug effects ; Bone Density Conservation Agents/therapeutic use ; Bone Remodeling/drug effects ; Double-Blind Method ; Drug Administration Schedule ; Female ; Humans ; Male ; Osteoporosis/complications ; Patient Compliance ; Risedronic Acid/adverse effects ; Risedronic Acid/pharmacology ; Spinal Fractures/complications ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Efficacy of combined medication of risedronate sodium and selective estrogen receptor modulator on the postmenopausal osteoporosis.
Autorzy :
Deng Y; Department of Nursing, Jingzhou Chinese Medicine Hospital of Hubei Province, Jingzhou, Hubei, China.
Li L; Department of Nursing, Jingzhou Chinese Medicine Hospital of Hubei Province, Jingzhou, Hubei, China.
Li C; Department of Orthopedics, Jingzhou Chinese Medicine Hospital of Hubei Province, Jingzhou, Hubei, China.
Wang F; Department of Physical Examination, Jingzhou Chinese Medicine Hospital of Hubei Province, Jingzhou, Hubei, China.
Qu Y; Department of Orthopedics Medical Center, the 2nd Hospital of Jilin University, Changchun, Jilin, China.
Pokaż więcej
Źródło :
Pakistan journal of pharmaceutical sciences [Pak J Pharm Sci] 2020 Jan; Vol. 33 (1(Special)), pp. 495-498.
Typ publikacji :
Journal Article
MeSH Terms :
Osteoporosis, Postmenopausal/*drug therapy
Raloxifene Hydrochloride/*administration & dosage
Risedronic Acid/*administration & dosage
Selective Estrogen Receptor Modulators/*administration & dosage
Aged ; Bone Density ; Bone and Bones/metabolism ; Drug Therapy, Combination ; Female ; Humans ; Middle Aged ; Raloxifene Hydrochloride/adverse effects ; Risedronic Acid/adverse effects
Czasopismo naukowe
Tytuł :
Upper gastrointestinal safety of oral bisphosphonate in hospitalized patients.
Autorzy :
Nguyen PV; Centre Hospitalier de l'Université de Montréal Research Center, Montreal, Canada. .; Quebec Network for Research on Aging, 1000 Rue Saint-Denis, Montréal, Québec, H2X 0C1, Canada. .
Bouin M; Centre Hospitalier de l'Université de Montréal Research Center, Montreal, Canada.
Ste-Marie LG; Centre Hospitalier de l'Université de Montréal Research Center, Montreal, Canada.
Pokaż więcej
Źródło :
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2021 Jan; Vol. 32 (1), pp. 193-197. Date of Electronic Publication: 2020 Jul 14.
Typ publikacji :
Journal Article
MeSH Terms :
Bone Density Conservation Agents*/adverse effects
Diphosphonates*/adverse effects
Osteoporosis*/drug therapy
Osteoporosis*/epidemiology
Administration, Oral ; Adult ; Aged ; Alendronate/adverse effects ; Humans ; Inpatients ; Middle Aged ; Prospective Studies ; Risedronic Acid/therapeutic use
Czasopismo naukowe
Tytuł :
Safety and efficacy of risedronate for patients with esophageal varices and liver cirrhosis: a non-randomized clinical trial.
Autorzy :
Lima TB; Internal Medicine Department, Gastroenterology Division - São Paulo State University (UNESP), Botucatu Medical School, São Paulo, Brazil.
Santos LAA; Internal Medicine Department, Gastroenterology Division - São Paulo State University (UNESP), Botucatu Medical School, São Paulo, Brazil.
Nunes HRC; Public Health Department, São Paulo State University (UNESP), Botucatu Medical School, São Paulo, Brazil.
Silva GF; Internal Medicine Department, Gastroenterology Division - São Paulo State University (UNESP), Botucatu Medical School, São Paulo, Brazil.
Caramori CA; Internal Medicine Department, Gastroenterology Division - São Paulo State University (UNESP), Botucatu Medical School, São Paulo, Brazil.
Qi X; General Hospital of Shenyang Military Command, Liaoning, Sheng, China.
Romeiro FG; Internal Medicine Department, Gastroenterology Division - São Paulo State University (UNESP), Botucatu Medical School, São Paulo, Brazil. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2019 Dec 12; Vol. 9 (1), pp. 18958. Date of Electronic Publication: 2019 Dec 12.
Typ publikacji :
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Esophageal and Gastric Varices/*drug therapy
Liver Cirrhosis/*drug therapy
Osteoporosis/*drug therapy
Risedronic Acid/*administration & dosage
Absorptiometry, Photon ; Adult ; Aged ; Calcium/administration & dosage ; Calcium/adverse effects ; Esophageal and Gastric Varices/complications ; Esophageal and Gastric Varices/pathology ; Female ; Follow-Up Studies ; Humans ; Liver Cirrhosis/complications ; Liver Cirrhosis/pathology ; Male ; Middle Aged ; Osteoporosis/etiology ; Osteoporosis/pathology ; Prospective Studies ; Risedronic Acid/adverse effects ; Vitamin D/administration & dosage ; Vitamin D/adverse effects
Czasopismo naukowe
Tytuł :
Risedronate Effects on the In Vivo Bioactive Glass Behavior: Nuclear Magnetic Resonance and Histopathological Studies.
Autorzy :
Mosbahi S; Univ Rennes, CNRS, ISCR-UMR 6226, F-3500Rennes, France.; Experimental Surgery of the Musculoskeletal System Laboratory, Sfax Faculty of Medicine, Sfax, Tunisia.
Oudadesse H; Univ Rennes, CNRS, ISCR-UMR 6226, F-3500Rennes, France.
Roiland C; Univ Rennes, CNRS, ISCR-UMR 6226, F-3500Rennes, France.
Lefeuvre B; Univ Rennes, CNRS, ISCR-UMR 6226, F-3500Rennes, France.
Slimani L; EA2496, Faculty of Dentistry, Paris Descartes University, Montrouge, France.
Keskes H; Experimental Surgery of the Musculoskeletal System Laboratory, Sfax Faculty of Medicine, Sfax, Tunisia.
Pokaż więcej
Źródło :
BioMed research international [Biomed Res Int] 2019 Dec 12; Vol. 2019, pp. 2175731. Date of Electronic Publication: 2019 Dec 12 (Print Publication: 2019).
Typ publikacji :
Journal Article
MeSH Terms :
Bone Density Conservation Agents/*pharmacology
Durapatite/*pharmacology
Glass/*chemistry
Osteoporosis/*drug therapy
Risedronic Acid/*pharmacology
Animals ; Bone Density/drug effects ; Bone Density Conservation Agents/chemistry ; Female ; Magnetic Resonance Spectroscopy ; Rats ; Rats, Wistar ; Risedronic Acid/chemistry
Czasopismo naukowe
Tytuł :
QbD Approach for Novel Crosslinker-Free Ionotropic Gelation of Risedronate Sodium-Chitosan Nebulizable Microspheres: Optimization and Characterization.
Autorzy :
Elkady OA; Department of Pharmaceutics, Faculty of Pharmacy, October University for Modern Sciences and Arts (MSA), Giza, 11787, Egypt.
Tadros MI; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, 11562, Egypt. .
El-Laithy HM; Department of Pharmaceutics, Faculty of Pharmacy, October University for Modern Sciences and Arts (MSA), Giza, 11787, Egypt.; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, 11562, Egypt.
Pokaż więcej
Źródło :
AAPS PharmSciTech [AAPS PharmSciTech] 2019 Dec 05; Vol. 21 (1), pp. 14. Date of Electronic Publication: 2019 Dec 05.
Typ publikacji :
Journal Article
MeSH Terms :
Microspheres*
Qualitative Research*
Chitosan/*chemistry
Risedronic Acid/*chemistry
Animals ; Biological Availability ; Chitosan/administration & dosage ; Drug Delivery Systems/methods ; Drug Liberation ; Gels ; Male ; Particle Size ; Rats ; Rats, Wistar ; Risedronic Acid/administration & dosage
Czasopismo naukowe
Tytuł :
Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan.
Autorzy :
Sugimoto T; Internal Medicine, 1, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.
Inoue D; Third Department of Medicine, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara-shi, Chiba, 299-0111, Japan. .
Maehara M; EA Pharma Co., Ltd., 2-1-1 Irifune, Chuo-ku, Tokyo, 104-0042, Japan.
Oikawa I; EA Pharma Co., Ltd., 2-1-1 Irifune, Chuo-ku, Tokyo, 104-0042, Japan.
Shigematsu T; Department of Nephrology, Wakayama Medical University, 811-1 Kimiidera, Wakayama-shi, Wakayama, 641-8509, Japan.
Nishizawa Y; Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan.; Inoue Hospital, 16-17 Enoki-cho, Suita-shi, Osaka, 564-0053, Japan.
Pokaż więcej
Źródło :
Journal of bone and mineral metabolism [J Bone Miner Metab] 2019 Jul; Vol. 37 (4), pp. 730-740. Date of Electronic Publication: 2018 Dec 06.
Typ publikacji :
Clinical Trial, Phase III; Journal Article
MeSH Terms :
Osteoporosis/*complications
Osteoporosis/*drug therapy
Renal Insufficiency, Chronic/*complications
Risedronic Acid/*adverse effects
Risedronic Acid/*therapeutic use
Aged ; Biomarkers/blood ; Biomarkers/urine ; Bone Density ; Bone Density Conservation Agents/administration & dosage ; Bone Density Conservation Agents/adverse effects ; Bone Density Conservation Agents/therapeutic use ; Bone Remodeling ; Calcium/blood ; Creatinine/blood ; Diphosphonates/administration & dosage ; Diphosphonates/adverse effects ; Diphosphonates/therapeutic use ; Double-Blind Method ; Drug Administration Schedule ; Female ; Glomerular Filtration Rate ; Humans ; Lumbar Vertebrae/physiopathology ; Male ; Middle Aged ; Osteoporosis/blood ; Osteoporosis/physiopathology ; Phosphorus/blood ; Renal Insufficiency, Chronic/blood ; Renal Insufficiency, Chronic/physiopathology ; Risedronic Acid/administration & dosage ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Autorzy :
Jakob T; Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Tesfamariam YM; Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Macherey S; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cochrane Haematological Malignancies, Cologne, Germany.
Kuhr K; Institute of Medical Statistics and Computational Biology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Adams A; Institute of Medical Statistics and Computational Biology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Monsef I; Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Heidenreich A; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Department of Urology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Skoetz N; Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Pokaż więcej
Źródło :
The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2020 Dec 03; Vol. 12. Cochrane AN: CD013020. Date of Electronic Publication: 2020 Dec 03.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms :
Bone Density Conservation Agents/*therapeutic use
Bone Neoplasms/*drug therapy
Bone Neoplasms/*secondary
Denosumab/*therapeutic use
Diphosphonates/*therapeutic use
Prostatic Neoplasms/*pathology
RANK Ligand/*antagonists & inhibitors
Adult ; Alendronate/adverse effects ; Alendronate/therapeutic use ; Antineoplastic Agents, Hormonal/therapeutic use ; Bisphosphonate-Associated Osteonecrosis of the Jaw/etiology ; Bone Density Conservation Agents/adverse effects ; Clodronic Acid/adverse effects ; Clodronic Acid/therapeutic use ; Denosumab/adverse effects ; Diphosphonates/adverse effects ; Etidronic Acid/adverse effects ; Etidronic Acid/therapeutic use ; Humans ; Male ; Network Meta-Analysis ; Pamidronate/adverse effects ; Pamidronate/therapeutic use ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms, Castration-Resistant/pathology ; Quality of Life ; Randomized Controlled Trials as Topic ; Risedronic Acid/adverse effects ; Risedronic Acid/therapeutic use ; Zoledronic Acid/adverse effects ; Zoledronic Acid/therapeutic use
Czasopismo naukowe
Tytuł :
Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia.
Autorzy :
Sestak I; Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University London, Charterhouse Square, London EC1M 6BQ, UK. Electronic address: .
Blake GM; School of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London SE1 7EH, UK.
Patel R; Imperial College London, London SW7 2AZ, UK.
Coleman RE; Department of Oncology and Metabolism, University of Sheffield, Western Bank, Sheffield S10 2TN, UK.
Cuzick J; Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University London, Charterhouse Square, London EC1M 6BQ, UK.
Eastell R; Department of Oncology and Metabolism, University of Sheffield, Western Bank, Sheffield S10 2TN, UK.
Pokaż więcej
Źródło :
Bone [Bone] 2019 Jul; Vol. 124, pp. 83-88. Date of Electronic Publication: 2019 Apr 24.
Typ publikacji :
Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Anastrozole/*adverse effects
Bone Diseases, Metabolic/*epidemiology
Bone Resorption/*chemically induced
Bone Resorption/*prevention & control
Breast Neoplasms/*epidemiology
Risedronic Acid/*therapeutic use
Bone Density/drug effects ; Bone Resorption/blood ; Bone Resorption/physiopathology ; Female ; Fractures, Bone/chemically induced ; Humans ; Middle Aged ; Peptide Fragments/blood ; Placebos ; Procollagen/blood ; Risedronic Acid/pharmacology ; Risk Factors
Czasopismo naukowe
Tytuł :
Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis.
Autorzy :
Liu Q; Department of Orthopaedics.
Chen D; Department of Orthopaedics.
Ye Z; Pharmaceutical Department.
Jin Z; Department of Critical Care Medicine.
Ma T; Department of Orthopaedics.
Huang X; Department of Gastroenterology, The First People's Hospital of Longquanyi District, Chengdu, Sichuan, China.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Oct 02; Vol. 99 (40), pp. e22542.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Diphosphonates/*therapeutic use
Imidazoles/*therapeutic use
Osteoporosis/*drug therapy
Aged ; Aged, 80 and over ; Alendronate/therapeutic use ; Alkaline Phosphatase/drug effects ; Bone Density Conservation Agents/therapeutic use ; Case-Control Studies ; Collagen Type I/drug effects ; Creatinine ; Drug Therapy, Combination/statistics & numerical data ; Female ; Humans ; Male ; Middle Aged ; Raloxifene Hydrochloride/therapeutic use ; Randomized Controlled Trials as Topic ; Risedronic Acid/therapeutic use ; Spinal Fractures/epidemiology ; Tartrate-Resistant Acid Phosphatase/drug effects ; Treatment Outcome ; Vitamin D/analogs & derivatives ; Vitamin D/therapeutic use
Czasopismo naukowe
Tytuł :
Efficacy of teriparatide compared with risedronate on FRAX -defined major osteoporotic fractures: results of the VERO clinical trial.
Autorzy :
Body JJ; CHU Brugmann, Université Libre de Bruxelles (ULB), Brussels, Belgium. .
Marin F; Lilly Research Center Europe, Madrid, Spain.
Kendler DL; University of British Columbia, Vancouver, Canada.
Zerbini CAF; Centro Paulista de Investigaçao Clínica, Sao Paulo, Brazil.
López-Romero P; Lilly Research Center Europe, Madrid, Spain.
Möricke R; Institut Präventive Medizin & Klinische Forschung, Magdeburg, Germany.
Casado E; University Hospital Parc Taulí Sabadell, Barcelona, Spain.
Fahrleitner-Pammer A; Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
Stepan JJ; Institute of Rheumatology and Faculty of Medicine 1, Charles University, Prague, Czech Republic.
Lespessailles E; Regional Hospital, University of Orleans, Orleans, France.
Minisola S; Sapienza Rome University, Rome, Italy.
Geusens P; Maastricht University Medical Center, Maastricht, The Netherlands.
Pokaż więcej
Źródło :
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2020 Oct; Vol. 31 (10), pp. 1935-1942. Date of Electronic Publication: 2020 May 30.
Typ publikacji :
Journal Article
MeSH Terms :
Bone Density Conservation Agents*/therapeutic use
Osteoporosis, Postmenopausal*/drug therapy
Osteoporotic Fractures*/epidemiology
Osteoporotic Fractures*/etiology
Osteoporotic Fractures*/prevention & control
Aged ; Bone Density ; Double-Blind Method ; Female ; Humans ; Risedronic Acid/therapeutic use ; Teriparatide/therapeutic use
Czasopismo naukowe
Tytuł :
Anionic versus cationic bilosomes as oral nanocarriers for enhanced delivery of the hydrophilic drug risedronate.
Autorzy :
Elnaggar YSR; Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt; Department of Pharmaceutics, Faculty of Pharmacy and Drug Manufacturing, Pharos University in Alexandria, Alexandria, Egypt. Electronic address: .
Omran S; Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
Hazzah HA; Department of Pharmaceutics, Faculty of Pharmacy and Drug Manufacturing, Pharos University in Alexandria, Alexandria, Egypt.
Abdallah OY; Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
Pokaż więcej
Źródło :
International journal of pharmaceutics [Int J Pharm] 2019 Jun 10; Vol. 564, pp. 410-425. Date of Electronic Publication: 2019 Apr 25.
Typ publikacji :
Journal Article
MeSH Terms :
Bile Acids and Salts/*administration & dosage
Bone Density Conservation Agents/*administration & dosage
Drug Carriers/*administration & dosage
Nanoparticles/*administration & dosage
Risedronic Acid/*administration & dosage
Administration, Oral ; Animals ; Anions ; Bile Acids and Salts/chemistry ; Bone Density Conservation Agents/chemistry ; Cations ; Drug Carriers/chemistry ; Drug Liberation ; Hydrophobic and Hydrophilic Interactions ; Intestinal Absorption ; Lipids/administration & dosage ; Lipids/chemistry ; Liposomes ; Male ; Nanoparticles/chemistry ; Rats, Wistar ; Risedronic Acid/chemistry
Czasopismo naukowe
Tytuł :
Improved treatment efficacy of risedronate functionalized chitosan nanoparticles in osteoporosis: formulation development, in vivo, and molecular modelling studies.
Autorzy :
Santhosh S; a Department of Pharmacology , M. S. Ramaiah University of Applied Sciences , Bengaluru , India.
Mukherjee D; b Department of Pharmaceutics , M.S. Ramaiah University of Applied Sciences , Bengaluru , India.
Anbu J; a Department of Pharmacology , M. S. Ramaiah University of Applied Sciences , Bengaluru , India.
Murahari M; c Pharmacological Modelling and Simulation Centre , M. S. Ramaiah University of Applied Sciences , Bengaluru , India.
Teja BV; d Department of Pharmaceutics , Central Drug Research Institute , Lucknow , India.
Pokaż więcej
Źródło :
Journal of microencapsulation [J Microencapsul] 2019 Jun; Vol. 36 (4), pp. 338-355. Date of Electronic Publication: 2019 Jun 27.
Typ publikacji :
Journal Article
MeSH Terms :
Bone Density Conservation Agents/*administration & dosage
Chitosan/*chemistry
Drug Carriers/*chemistry
Nanoparticles/*chemistry
Osteoporosis/*drug therapy
Risedronic Acid/*administration & dosage
Animals ; Bone Density/drug effects ; Bone Density Conservation Agents/therapeutic use ; Female ; Rats, Wistar ; Risedronic Acid/therapeutic use
Czasopismo naukowe
Tytuł :
Bioactive injectable triple acting thermosensitive hydrogel enriched with nano-hydroxyapatite for bone regeneration: in-vitro characterization, Saos-2 cell line cell viability and osteogenic markers evaluation.
Autorzy :
Morsi NM; a Faculty of Pharmacy, Department of Pharmaceutics and Industrial Pharmacy , Cairo University , Cairo , Egypt.
Nabil Shamma R; a Faculty of Pharmacy, Department of Pharmaceutics and Industrial Pharmacy , Cairo University , Cairo , Egypt.
Osama Eladawy N; a Faculty of Pharmacy, Department of Pharmaceutics and Industrial Pharmacy , Cairo University , Cairo , Egypt.
Abdelkhalek AA; b Faculty of Oral and Dental Medicine, Department of Microbiology of Supplementary General Science , Future University in Egypt , Egypt.
Pokaż więcej
Źródło :
Drug development and industrial pharmacy [Drug Dev Ind Pharm] 2019 May; Vol. 45 (5), pp. 787-804. Date of Electronic Publication: 2019 Feb 04.
Typ publikacji :
Journal Article
MeSH Terms :
Bone Density Conservation Agents/*administration & dosage
Bone Regeneration/*drug effects
Durapatite/*chemistry
Osteogenesis/*drug effects
Risedronic Acid/*administration & dosage
Bone Cements/chemistry ; Bone Density Conservation Agents/pharmacokinetics ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Chitosan/chemistry ; Drug Liberation ; Glycerophosphates/chemistry ; Humans ; Hydrogels/chemistry ; Materials Testing ; Nanoparticles/chemistry ; Porosity ; Risedronic Acid/pharmacokinetics ; Temperature ; Tissue Engineering/methods
Czasopismo naukowe
Tytuł :
Symptoms and Upper Gastrointestinal Mucosal Injury Associated with Bisphosphonate Therapy.
Autorzy :
Yamamoto K; Department of Internal Medicine and Gastroenterology, Tokyo Women's Medical University, Japan.
Kishino M; Department of Internal Medicine and Gastroenterology, Tokyo Women's Medical University, Japan.
Nakamura S; Department of Internal Medicine and Gastroenterology, Tokyo Women's Medical University, Japan.
Tokushige K; Department of Internal Medicine and Gastroenterology, Tokyo Women's Medical University, Japan.
Pokaż więcej
Źródło :
Internal medicine (Tokyo, Japan) [Intern Med] 2019 Apr 15; Vol. 58 (8), pp. 1049-1056. Date of Electronic Publication: 2019 Jan 10.
Typ publikacji :
Journal Article
MeSH Terms :
Alendronate/*adverse effects
Bone Density Conservation Agents/*adverse effects
Gastrointestinal Tract/*drug effects
Mucous Membrane/*drug effects
Osteoporosis/*drug therapy
Risedronic Acid/*adverse effects
Adult ; Aged ; Aged, 80 and over ; Alendronate/therapeutic use ; Bone Density Conservation Agents/therapeutic use ; Female ; Gastrointestinal Tract/injuries ; Humans ; Japan ; Male ; Middle Aged ; Mucous Membrane/injuries ; Risedronic Acid/therapeutic use
Czasopismo naukowe
Tytuł :
Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
Autorzy :
Hiligsmann M; Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, P.O. Box 616, 6200, MD, Maastricht, The Netherlands. .
Reginster JY; Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.; Prince Mutaib Chair for Biomarkers of Osteoporosis, Biochemistry Department, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia.
Pokaż więcej
Źródło :
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2019 Mar; Vol. 30 (3), pp. 649-658. Date of Electronic Publication: 2019 Jan 30.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Bone Density Conservation Agents/*economics
Health Care Costs/*statistics & numerical data
Osteoporosis, Postmenopausal/*economics
Risedronic Acid/*economics
Administration, Oral ; Aged ; Aged, 80 and over ; Alendronate/economics ; Alendronate/therapeutic use ; Bone Density Conservation Agents/administration & dosage ; Bone Density Conservation Agents/therapeutic use ; Cost-Benefit Analysis ; Delayed-Action Preparations/administration & dosage ; Delayed-Action Preparations/economics ; Delayed-Action Preparations/therapeutic use ; Drug Costs/statistics & numerical data ; Female ; France ; Humans ; Markov Chains ; Middle Aged ; Models, Econometric ; Osteoporosis, Postmenopausal/drug therapy ; Osteoporotic Fractures/economics ; Osteoporotic Fractures/prevention & control ; Quality-Adjusted Life Years ; Risedronic Acid/administration & dosage ; Risedronic Acid/therapeutic use
Czasopismo naukowe
Tytuł :
Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study.
Autorzy :
Lee DR; Department of Family Medicine, Wonkwang University School of Medicine, Wonkwang University Sanbon Hospital, 321, Sanbon-ro, Gunpo-si, 15865, Gyeonggi-do, Republic of Korea. .
Lee J; Department of Family Medicine, Wonkwang University School of Medicine, Wonkwang University Sanbon Hospital, 321, Sanbon-ro, Gunpo-si, 15865, Gyeonggi-do, Republic of Korea.
Pokaż więcej
Źródło :
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2019 Mar; Vol. 30 (3), pp. 659-666. Date of Electronic Publication: 2018 Dec 08.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Bone Density Conservation Agents/*therapeutic use
Ibandronic Acid/*therapeutic use
Osteoporosis, Postmenopausal/*drug therapy
Risedronic Acid/*therapeutic use
Administration, Oral ; Aged ; Bone Density Conservation Agents/administration & dosage ; Databases, Factual ; Drug Administration Schedule ; Female ; Humans ; Ibandronic Acid/administration & dosage ; Incidence ; Middle Aged ; Osteoporosis, Postmenopausal/epidemiology ; Osteoporotic Fractures/epidemiology ; Osteoporotic Fractures/prevention & control ; Republic of Korea/epidemiology ; Retrospective Studies ; Risedronic Acid/administration & dosage
Czasopismo naukowe
Tytuł :
Risedronate-Loaded Macroporous Gel Foam Enriched with Nanohydroxyapatite: Preparation, Characterization, and Osteogenic Activity Evaluation Using Saos-2 Cells.
Autorzy :
Morsi NM; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Shamma RN; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt. .
Eladawy NO; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Abdelkhalek AA; Department of Microbiology of Supplementary General Science, Faculty of Oral and Dental Medicine, Future University in Egypt, Cairo, Egypt.
Pokaż więcej
Źródło :
AAPS PharmSciTech [AAPS PharmSciTech] 2019 Feb 08; Vol. 20 (3), pp. 104. Date of Electronic Publication: 2019 Feb 08.
Typ publikacji :
Journal Article
MeSH Terms :
Nanostructures*
Bone Density Conservation Agents/*pharmacology
Durapatite/*pharmacology
Osteogenesis/*drug effects
Poloxamer/*pharmacology
Risedronic Acid/*administration & dosage
Alginates/administration & dosage ; Cell Line, Tumor ; Drug Liberation ; Durapatite/chemistry ; Humans ; Methylcellulose/pharmacology ; Porosity ; Risedronic Acid/pharmacology
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies